Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: Definition of clinical target volume for radiotherapy

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Wang, Weihu ^a   Feng, Xiaoli ^a   Zhang, Tao ^a   Jin, Jing ^a   Wang, Shulian ^a   Liu, Yueping ^a   Song, Yongwen ^a   Liu, Xinfan ^a   Yu, Zihao ^a   Li, Yexiong ^a  

^a CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; TISSUE SECTION; HISTOLOGY; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; ONCOLOGY; PATHOLOGY; RADIATION DOSE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HISTOLOGICAL TECHNIQUES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIATION ONCOLOGY; RADIOTHERAPY DOSAGE;

EID: 77955779587     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-73     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001, 94:153-156. 10.1002/ijc.1440, 11668491.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
3. Zhang SW, Chen WQ, Lei ZL, et al. A report of cancer incidence from 37 cancer registries in China, 2004. China Cancer 2008, 17:909-912.
4. Chen WQ, Zhang SW, Kong LZ, et al. Cancer mortality report of 34 cancer registries in China, 2004. China Cancer 2008, 17:913-916.
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
6. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005, 40:225-235. 10.1007/s00535-005-1566-3, 15830281.
7. Choi TK, Edward CS, Fan ST, et al. Results of surgical resection for hepatocellular carcinoma. Hepatogastroenterology 1990, 37:172-175.
8. Nagorney DM, van Heerden JA, Ilstrup DM, et al. Primary hepatic malignancy: surgical management and determinants of survival. Surgery 1989, 106:740-748.
9. Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006, 106:1653-1663. 10.1002/cncr.21811, 16541431.
10. Fukumitsu N, Sugahara S, Nakayama H, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009, 74:831-836.
11. Park W, Lim DH, Paik SW, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005, 61:1143-1150.
12. Mornex F, Girard N, Beziat C, et al. Feasibility and efficacy of high-dose three-dimensional radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006, 66:1152-1158.
13. Kim TH, Kim DY, Park JW, et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 2006, 29:568-575. 10.1097/01.coc.0000239147.60196.11, 17148993.
14. Jenkins P, Anjarwalla S, Gilbert H, et al. Defining the clinical target volume for bladder cancer radiotherapy treatment planning. Int J Radiat Oncol Biol Phys 2009, 75(5):1379-84.
15. Apisarnthanarax S, Elliott DD, El-Naggar AK, et al. Determining optimal clinical target volume margins in head-and neck cancer based on microscopic extracapsular extension of metastatic neck nodes. Int J Radiat Oncol Biol Phys 2006, 64:678-683.
16. Yuan S, Meng X, Yu J, et al. Determining optimal clinical target volume margins on the basis of microscopic extracapsular extension of metastatic nodes in patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2007, 67:727-734.
17. Chao KK, Goldstein NS, Yan D, et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension?. Int J Radiat Oncol Biol Phys 2006, 65:999-1007.
18. Schwartz DJ, Sengupta S, Hillman DW, et al. Prediction of radial distance of extraprostatic extension from pretherapy factors. Int J Radiat Oncol Biol Phys 2007, 69:411-418.
19. Teh BS, Bastasch MD, Wheeler TM, et al. IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys 2003, 56:184-191.
20. Grills IS, Fitch DL, Goldstein NS, et al. Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy. Int J Radiat Oncol Biol Phys 2007, 69:334-341.
21. Giraud P, Antoine M, Larrouy A, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000, 48:1015-1024. 10.1016/S0360-3016(00)00750-1, 11072158.
22. Choo R, Woo T, Assaad D, et al. What is the microscopic tumor extent beyond clinically delineated gross tumor boundary in nonmelanoma skin cancers?. Int J Radiat Oncol Biol Phys 2005, 62:1096-1099.
23. Wang MH, Ji Y, Zeng ZC, et al. Impact Factors for Microinvasion in Patients with Hepatocellular Carcinoma: Possible Application to the Definition of Clinical Tumor Volume. Int J Radiat Oncol Biol Phys 2009,
24. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000, 18:2210-2218.
25. Park HC, Seong J, Han KH, et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002, 54:150-155. 10.1016/S0360-3016(02)03283-2, 12182985.
26. Liu MT, Li SH, Chu TC, et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol 2004, 34:532-539. 10.1093/jjco/hyh089, 15466827.
27. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005, 23:8739-8747. 10.1200/JCO.2005.01.5354, 16314634.
28. Seong J, Park HC, Han KH, et al. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003, 55:329-336.
29. Carr BI, Buch SC, Kondragunta V, et al. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: A case cohort study. J Gastroenterol Hepatol 2008, 23:1259-1266. 10.1111/j.1440-1746.2008.05487.x, 18699979.
30. Changchien CS, Chen CL, Yen YH, et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: Prognostic features, treatment outcome, and survival. J Gastroenterol 2008, 43:159-170. 10.1007/s00535-007-2134-9, 18306990.
31. Montorsi M, Santambrogio R, Bianchi P, et al. Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. J Gastrointest Surg 2005, 9:62-67. 10.1016/j.gassur.2004.10.003, 15623446.
32. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38:200-207. 10.1016/S0168-8278(02)00360-4, 12547409.
33. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999, 31:133-141. 10.1016/S0168-8278(99)80173-1, 10424293.
34. Hanazachi K, Kajikawa S, Koide N, et al. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: Univariate and multivariate analysis. Am J Gastroenterol 2001, 96:1243-1250. 10.1111/j.1572-0241.2001.03634.x, 11316177.
35. Matsumoto K, Yoshimoto J, Sugo H, et al. Relationship between the histological degrees of hepatitis and the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis C. Hepatol Res 2002, 23:196-201. 10.1016/S1386-6346(01)00180-2, 12076715.
36. Harrison LEH, Koneru B, Baramipour P, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 2003, 197:759-764. 10.1016/S1072-7515(03)00750-6, 14585410.
37. Shah S, Cleary SP, Wei MA, et al. Recurrence after liver resection for hepatocellular carcinoma: Risk factors, treatment, and outcomes. Surgery 2007, 141:330-339. 10.1016/j.surg.2006.06.028, 17349844.
38. Cucchetti A, Vivarelli M, Piscaglia F, et al. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J Hepatol 2005, 43:310-316. 10.1016/j.jhep.2005.03.014, 15970351.
39. Wayne JD, Lauwers GY, Ikai I, et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 2002, 235:722-731. 10.1097/00000658-200205000-00015, 1422499, 11981219.
40. Wheeler TM, Dillioglugil O, Kattan MW, et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol 1998, 29:856-862. 10.1016/S0046-8177(98)90457-9, 9712429.
41. Schned A, Wheeler K, Hodorowski C, et al. Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol 1996, 20:1501-1506. 10.1097/00000478-199612000-00009, 8944043.